News and Trends 4 Mar 2015
Bristol-Myers Squibb signs an agreement for Bavarian Nordic’s PROSTVAC
Bristol-Myers Squibb signs an exclusive agreement with Bavarian Nordic for PROSTVAC, a prostate-specific antigen-targeting cancer immunotherapy. Bavarian Nordic will receive up to €880.4M. Bristol-Myers Squibb will have the exclusive option to license and commercialize PROSTVAC, Bavarian Nordic’s investigational Phase III prostate-specific antigen (PSA) in development for the treatment of asymptomatic or minimally symptomatic metastatic castration-resistant […]
